On the occasion of the Vienna Cancer Day on February 12th, the Medical University of Vienna mentioned the introduction of new substances as well as the increasing personalization of therapies. By introducing targeted therapies, the increasing individualization of therapy was made possible in the sense of “customized” therapies. The constant identification of new target molecules enables an increasing number of patients to undergo so-called personalized therapy” (precision medicine). The pre-requisite for this is evidence of defined mutations in the tumor tissue of the respective patient.
An impressive development can be observed with respect to immunotherapy. “It increasingly offers us the opportunity to provide therapy with a broad spectrum of drugs which can be individually tailored to the specific medical condition of the respective patients”, reported Christoph Zielinski, Head of the Comprehensive Cancer Center (CCC) of the Medical University of Vienna and Vienna General Hospital and Scientific Director of the Vienna Cancer Center.